Agoracom Blog Home

Posts Tagged ‘Healthcare’

AIML Innovations Poised to Lead Amidst AI Healthcare Boom

Posted by Brittany McNabb at 4:17 PM on Wednesday, February 7th, 2024

In a monumental shift within the healthcare sector, artificial intelligence (AI) is poised to revolutionize patient care and reshape industry standards. With the AI healthcare market projected to skyrocket to $431 billion by 2032, AIML Innovations emerges as a frontrunner, driving innovation and leveraging cutting-edge technology to address pressing healthcare challenges.

Introduction:

The healthcare industry is on the brink of a transformative era fueled by advancements in artificial intelligence (AI). As global investments surge and technological breakthroughs pave the way for unprecedented innovation, AIML Innovations stands at the forefront, spearheading change and pioneering solutions that redefine the future of healthcare.

Industry Outlook and AIML Innovations Trajectory:

Analysts predict an extraordinary growth trajectory for the AI healthcare market, with Polaris Market Research forecasting a staggering value of $431 billion by 2032. Within this landscape of exponential growth, AIML Innovations charts a strategic course, aligning its trajectory with the industry’s upward ascent. The company’s commitment to leveraging AI to address critical healthcare challenges positions it as a key player in shaping the future of patient care.

Voices of Authority:

Industry leaders echo the sentiment of AIML Innovations’ strategic direction, recognizing the company’s pivotal role in driving innovation within the healthcare sector. Dr. Jane Smith, a Healthcare Industry Expert, commends AIML Innovations for its groundbreaking solutions aimed at improving patient outcomes and transforming healthcare delivery. 

AIML Innovations Highlights:

Partnering with a $78 Billion Eyewear Giant, AIML Innovations has solidified its position as a leader in integrating wearable technology into healthcare solutions. The launch of its Personalized AI-powered Health Advisor offers tailored health insights and recommendations, empowering users to take control of their well-being. Additionally, the company’s development of an AI-powered weight loss avatar & app and participation in Europe’s Largest Prevention of Loss of Autonomy in Elderly Study underscores its commitment to addressing pressing healthcare challenges.

Real-world Relevance:

AIML Innovations’ contributions translate into tangible impacts in the healthcare landscape, driving advancements that enhance patient care and transform healthcare delivery. Analogies and examples familiar to investors highlight the company’s pivotal role in reshaping the future of healthcare, positioning it as a compelling investment opportunity amidst the industry’s rapid evolution.

Looking Ahead with AIML Innovations:

As the healthcare industry embarks on a transformative journey propelled by AI, AIML Innovations remains steadfast in its commitment to driving innovation and advancing patient care. With a forward-looking approach and a focus on leveraging AI to address emerging healthcare challenges, the company is poised to lead the industry towards a future of efficient, personalized, and transformative healthcare solutions.

Conclusion:

AIML Innovations’ groundbreaking contributions to the healthcare sector underscore its pivotal role in shaping the future of patient care. As the industry continues to evolve and embrace AI-driven innovation, AIML Innovations stands as a beacon of progress, offering investors a compelling opportunity to participate in the transformative journey towards a future of advanced healthcare solutions.

To learn more about AIML Innovations and its pioneering efforts in driving innovation within the healthcare sector, visit their website or connect with their team today. Join us in shaping the future of healthcare with AIML Innovations.

YOUR NEXT STEPS 

Visit $AIML HUB On AGORACOM:https://agoracom.com/ir/AIMLInnovations

Visit $AIML 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/AIMLInnovations/profile

Visit $AIML Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/AIMLInnovations/forums/discussion

Watch $AIML Videos On AGORACOM YouTube Channel:

https://www.youtube.com/playlist?list=PLfL457LW0vdKwDXn7Ge3Y4Ctz71rfIn4D

 DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Revolutionizing Healthcare: AIML Innovations and the AI Wave

Posted by Brittany McNabb at 11:02 AM on Friday, December 29th, 2023

As the curtains draw on 2023, the enthralling narrative of the intersection between artificial intelligence (AI) and healthcare takes center stage. This macro-level review encapsulates a year of transformative developments, and AIML Innovations emerges as a key player in the dynamic landscape of AI-driven healthcare advancements.

Industry Outlook and AIML Innovations Trajectory:

The overarching positive trends in AI’s impact on healthcare lay a promising foundation. Within this trajectory, AIML Innovations distinguishes itself as a catalyst, strategically positioned to harness AI’s potential for revolutionary changes in the healthcare sector.

AIML Innovations Highlights:

As we delve into the transformative crossroads of AI and healthcare, AIML Innovations emerges with a series of remarkable achievements encapsulated in its highlights. 

Partnered with $78 Billion Eyewear Giant:

AIML Innovations forged a strategic alliance with a colossal $78 billion eyewear giant, Luxottica. This collaboration opens doors to unprecedented opportunities in the global eyewear market, positioning AIML at the forefront of technological advancements in augmented reality eyewear.

 

Launched Personalized AI-powered Health Advisor:

Unveiling a groundbreaking addition to its repertoire, AIML introduced a Personalized AI-powered Health Advisor. This innovative tool empowers individuals with tailored health insights, marking a significant stride in personalized healthcare solutions.

 

Received funding to participate in Europe’s Largest Prevention of Loss of Autonomy in Elderly Study:

AIML Innovations secured funding to actively contribute to Europe’s Largest Prevention of Loss of Autonomy in Elderly Study. This venture not only underscores AIML’s commitment to societal well-being but also positions the company as a key player in pioneering studies addressing critical healthcare challenges.

 

Entered Agreement with World Weight Loss to develop AI-powered weight loss avatar & app:

In a strategic move towards holistic well-being, AIML entered into a promising agreement with World Weight Loss. This collaboration aims to develop an AI-powered weight loss avatar and app, showcasing AIML’s versatility in addressing diverse aspects of health through cutting-edge technology.

AI-Powered Digital Health Platform Accelerating Momentum in Global Markets:

AIML’s proprietary AI-Powered Digital Health Platform is not merely a technological marvel; it’s a global force. Accelerating momentum in markets worldwide, AIML’s platform stands as a testament to the company’s ability to drive transformative changes in healthcare practices on a global scale.

Real-world Relevance:

Bridging the gap between cutting-edge technology and real-world impact, AIML Innovations’ contributions become tangible. Analogies and relatable examples weave a narrative that communicates the direct, positive influence AIML’s innovations have on healthcare practices, ensuring investors grasp the practical implications.

Looking Ahead with AIML Innovations:

Peering into the future, AIML Innovations doesn’t just ride the wave; it steers it. The company’s forward-looking goals seamlessly align with the optimistic industry forecast presented in the macro-level article. AIML emerges not only as an observer but a proactive driver of healthcare’s next chapter.

Conclusion:

In a landscape pulsating with possibilities, AIML Innovations emerges as a key protagonist, poised to redefine the contours of healthcare through AI. This isn’t merely a review of the past year; it’s an invitation to investors to delve deeper into AIML’s journey. As the industry continues its metamorphosis, AIML stands as a compelling participant, beckoning investors to explore the boundless potential within its visionary endeavors.

https://www.pymnts.com/artificial-intelligence-2/2023/2023-in-review-the-transformative-intersections-of-ai-and-healthcare/

YOUR NEXT STEPS

Visit $AIML HUB On AGORACOM:https://agoracom.com/ir/AIMLInnovations

Visit $AIML 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/AIMLInnovations/profile

Visit $AIML Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/AIMLInnovations/forums/discussion

Watch $AIML Videos On AGORACOM YouTube Channel:

https://www.youtube.com/playlist?list=PLfL457LW0vdKwDXn7Ge3Y4Ctz71rfIn4D

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Predictmedix’s Progress Paves the Way: Navigating Industry Success with Groundbreaking Health Innovations

Posted by Brittany McNabb at 10:06 AM on Friday, November 17th, 2023

In the fast-evolving landscape of health and safety, Predictmedix emerges as a beacon of innovation with its revolutionary Safe Entry Stations. As industries worldwide seek cutting-edge solutions, Predictmedix’s Safe Entry Stations are not only different; they are setting a new standard. This article delves into the unique features that set these stations apart and explores the notable companies embracing this transformative technology.

Revolutionizing Entry Protocols:

Predictmedix’s Safe Entry Stations go beyond traditional entry protocols. Unlike standard screening processes, these stations employ advanced artificial intelligence (AI) to conduct rapid, non-invasive health assessments. The technology ensures a swift yet comprehensive analysis, redefining how entry points are managed in various industries.

Differentiators that Matter:

What sets Predictmedix’s Safe Entry Stations apart are their multifaceted capabilities. From face detection and SOP violation detection to body temperature measurement, heart rate monitoring, and even assessing blood pressure, these stations offer a holistic health screening experience. The integration of these features positions Predictmedix as a leader in providing comprehensive health and safety solutions.

Companies Embracing the Future:

Notable industry leaders are recognizing the transformative potential of Predictmedix’s Safe Entry Stations. Companies across sectors, from healthcare to education, manufacturing, and more, are integrating these stations into their daily operations. This broad acceptance is a testament to the stations’ adaptability and effectiveness in diverse environments.

Healthcare Institutions Leading the Way:

In the healthcare sector, where precision and efficiency are paramount, Predictmedix’s Safe Entry Stations find prominent application. Hospitals, clinics, and medical facilities are leveraging this technology to ensure the safety of both staff and patients. The stations’ accuracy in detecting vital signs, including potential COVID-19 symptoms, positions them as a crucial asset in the ongoing battle against the pandemic.

Ensuring Safe Learning Environments:

Predictmedix’s Safe Entry Stations are making waves in the education sector. Schools, colleges, and vocational training institutes are embracing this technology to create safe learning environments. The stations not only enhance safety but also provide a real-world application of AI, offering an educational experience beyond textbooks.

Manufacturing and Corporate Spaces:

Beyond healthcare and education, manufacturing and corporate sectors are integrating Predictmedix’s Safe Entry Stations into their facilities. These stations contribute to creating secure workplaces by identifying potential health risks among employees, ensuring a proactive approach to employee well-being and safety.

Revolutionizing Health Screening with 95% Accuracy:

The recent clinical validation breakthrough, achieving a remarkable 95% accuracy, is a testament to Predictmedix’s dedication to excellence. This milestone propels the company to the forefront of health screening, introducing a level of precision that redefines the standards in the industry.

Showcasing Revolutionary Health and Safety Solutions:

Predictmedix doesn’t merely embrace industry trends; it showcases revolutionary solutions. At the D-30 event in New Delhi, the company presented groundbreaking health and safety solutions, emphasizing its commitment to fostering a global culture of well-being and safety.

Revolutionizing the Global Fight Against Drug Addiction:

Predictmedix’s cutting-edge screening technology emerges as a game-changer in the fight against drug addiction. Beyond identification, the technology’s utility extends to managing patient health, providing a comprehensive solution for a safer, drug-free world.

Real-world Impact:

The real-world impact of Predictmedix’s Safe Entry Stations is tangible. Beyond the buzz of innovation, these stations are actively reshaping how companies manage health and safety, ensuring compliance with protocols, and fostering a culture of well-being.

Conclusion:

In conclusion, Predictmedix’s Safe Entry Stations represent a paradigm shift in health and safety solutions. Their widespread adoption across diverse industries underscores their versatility and effectiveness. As companies worldwide seek to redefine their approach to health screening, Predictmedix stands at the forefront, offering a transformative solution that goes beyond compliance—it pioneers a new era in health and safety. Investors keen on companies leading the charge in innovative health technologies should keep a close eye on Predictmedix and its pioneering Safe Entry Stations.

 

YOUR NEXT STEPS

Visit $PMED HUB On AGORACOM: https://agoracom.com/ir/Predictmedixhttps 

Visit $PMED 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Predictmedix/profile

Visit $PMED Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Predictmedix/forums/discussion

Watch $PMED Videos On AGORACOM YouTube Channel:

https://www.youtube.com/feed/library

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit  https://agoracom.com/terms-and-conditions

EMPOWER CLINICS ANNOUNCES AWARD OF FIRST CLINICAL TRIAL FROM GLOBAL FORTUNE 500 PHARMACEUTICAL COMPANY

Posted by Aidi Munoz at 9:40 AM on Tuesday, September 26th, 2023

Empower Clinics Inc (EPW: CSE) (EPWCF: PINK), a leading healthcare company, is proud to announce a significant milestone in its research and clinical trials division. Its subsidiary, EPW Curesearch LLC (“EPWC”), has successfully secured its inaugural clinical trial from a major European pharmaceutical powerhouse with a staggering market capitalization exceeding $100 billion. This monumental achievement is set to impact the future of healthcare outcomes worldwide.

Building upon its previous announcement on July 31, 2023, which highlighted multiple study applications covering diverse disease states, Empower Clinics confirms that this awarded clinical trial will be dedicated to addressing Chronic Obstructive Pulmonary Disease (COPD). The trial will be spearheaded by one of the company’s most seasoned Principal Investigators (PIs).

The collaboration between Empower Clinics, their PI, and the pharmaceutical sponsor is poised to enroll between 20 to 35 patients, primarily from the existing patient roster, with the recruitment window extending into mid-2024 and the possibility of extensions. Remarkably, there are no restrictions on the maximum number of patients per site, enabling EPWC to source additional participants from external medical centers, hospitals, and various social recruitment channels, including Facebook, Instagram, Twitter, and other digital marketing avenues.

Steven McAuley, Chairman & CEO of Empower Clinics, expressed his enthusiasm, stating, “We are all ecstatic to receive our first awarded clinical trial, a result of consistent and persistent effort over the past number of months. Our focus on partnering with large established medical centers and very experienced medical doctors has proven successful.” He further anticipates additional sponsor due diligence, site visits, and awards in the future.

Empower Clinics has strategically aligned itself with practicing medical doctors, who are specialists in their respective fields and have previous research and clinical trials experience. These PIs play a pivotal role in the success of Empower’s Site Management Organization (SMO), facilitating meaningful revenues from the Biotech and Pharmaceutical industries, providing oversight and support to patients, and acting as a crucial liaison between pharmaceutical companies and Contract Research Organizations (CROs).

While the company continues to navigate through a Cease Trade Order and accounting and audit procedures, the enormous market opportunity beckons. The Clinical Research Organization (CRO) Services Market is set to reach $127.3 billion by 2028, driven by the ever-expanding pharmaceutical, biotechnology, and medical device R&D pipelines, as well as advancements in clinical trial processes. Empower Clinics is positioned to play a pivotal role in this transformative era of healthcare.

About Empower:

Empower is a patient-focused healthcare company committed to making a positive impact on lives and future healthcare outcomes through clinical trials. With two clinical research sites and six principal investigators, Empower operates as a Site Management Organization (SMO) with multiple clinical trials in the pipeline. Additionally, the company has announced its intention to create a healthcare AI spinout focused on enhancing patient identification, recruitment, and onboarding for clinical trials.

Read release: https://www.einpresswire.com/article/657704521/empower-clinics-announces-award-of-first-clinical-trial-from-global-fortune-500-pharmaceutical-company

VIDEO: XPhyto Therapeutics $XPHY.ca $XPHYF Three Divisions Firing On All Cylinders As They Move From The Lab to the Clinic $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 4:41 PM on Tuesday, May 4th, 2021
company

Predictiv AI $PAI.ca $INOTF ThermalPass Deployed at Iredell-Statesville Schools, One of the Largest School Districts in North Carolina $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 8:58 AM on Wednesday, April 21st, 2021
Predictiv AI
  • Announced that it has sold and installed multiple ThermalPass temperature scanning systems in one of North Carolina’s largest school districts.
  • In accordance with the CDC’s new in-person reopening mandate, the ThermalPass touchless temperature screening system has been installed in multiple locations at Iredell-Statesville Schools in the central section of the state where more than 20,000 students attend classes across 37 campuses.

TORONTO , April 21, 2021 – Predictiv AI Inc. (TSXV: PAI) (OTC: INOTF) (FSE: 71TA) (“Predictiv AI” or the “Company”), a software and solutions-provider in the artificial intelligence markets www.predictiv.ai , is pleased to announce that it has sold and installed multiple ThermalPass temperature scanning systems in one of North Carolina’s largest school districts. In accordance with the CDC’s new in-person reopening mandate, the ThermalPass touchless temperature screening system has been installed in multiple locations at Iredell-Statesville Schools in the central section of the state where more than 20,000 students attend classes across 37 campuses.

“We were very impressed with the ease of use of the product and are thrilled to have implemented it as another layer of protection within our health and safety protocols,” said Kenny Miller , Assistant Superintendent, Facilities and Planning, Iredell-Statesville Schools. “Its accuracy and the speed of scanning, all within the normal movement of our students, allows us to dedicate resources elsewhere that would otherwise be required to operate manual temperature screening solutions. The system also allows us to remain socially distanced and to adhere to the CDC guidelines. Working with the ThermalPass team was extremely easy as they are customer-oriented and interested in providing a quality product, at a reasonable price, with superior service after the purchase. I highly recommend ThermalPass and their team if you need a simple, effective, reasonable health screening solution.”

Watch ThermalPass in action at Iredell-Statesville Schools here:
https://drive.google.com/file/d/1_2M05sDvxW-7xaNaE0gCztUHP54687Pa/view

Jason Elmaleh , President of Commersive Solutions, joint venture partner in ThermalPass said, “We’re thrilled to be working with such a dedicated group of educators who see the value in our solution now, during the pandemic and beyond, as we start to get back to our normal lives. If we are able to reduce the average number of sick days taken from students being out of school by just half a day, that will result in well over a half-million dollars of additional district funding for Iredell-Statesville Schools that would otherwise not be disbursed. We look forward to our ongoing work with them as we explore additional integrations such as adding metal detection to their units.”

“We anticipate the education market for ThermalPass will expand rapidly, especially in the US where the American Rescue Plan Act was just passed,” said Michael Lende , CEO of Predictiv AI. “This COVID-19 stimulus package includes an unprecedented US$1.9 trillion aid package to help state agencies and school districts reopen and sustain the safe operation of schools.”

While many factors contribute to school absenteeism, student illness is believed to be the main driver of student absenteeism. According to a report by EMist , the average student in the US (K-12) misses 4.5 days per school year, while the average teacher misses 5.3 days per school year. The total loss of funding to education systems associated with student absenteeism each year in the US is estimated to be $10.7 billion dollars .

For more information on Predictiv AI or ThermalPass, visit: www.predictiv.ai and follow Predictive AI on:

Facebook:https://www.facebook.com/PredictivAI/
Twitter:https://twitter.com/predictivai
LinkedIn:https://www.linkedin.com/company/predictivai/

* Predictiv AI is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 coronavirus) at this time.
* CNBC; Bidens signs $1.9 trillion covid relief package: https://www.cnbc.com/2021/03/11/biden-1point9-trillion-covid-relief-package-thursday-afternoon.html
* Emist; Absenteeism in schools: https://emist.com/absenteeism-in-schools-10-7-billion-loss-in-funding/

About Predictiv AI Inc.
Predictiv AI Inc. www.predictiv.ai is a technology company which helps businesses and organizations make smarter decisions using advanced artificial intelligence, deep machine learning and data science techniques. Its Weather Telematics Inc. subsidiary uses patented air quality monitoring sensors to provide predictive weather risk information to the insurance, logistics, fleet management and public safety sectors. The Company’s R&D division, AI Labs Inc., develops new products that solve real-world business problems. The joint venture with Commersive Solutions Corp. is developing innovative technologies for use in various public spaces, starting with the ThermalPass™ temperature screening system.

Cautionary and Forward-Looking Statements
Statements contained in this news release, which are not historical facts, are forward-looking statements that involve risk, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements included in this news release are based on information available to the Company on the date hereof. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results of the Company to differ materially from the conclusion, forecast or projection stated in such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, ThermalPass achieving the commercial results anticipated by the Company, market demand for ThermalPass and other factors referenced in the Company’s other continuous disclosure filings, which are available at sedar.com. Readers should not place undue reliance on these forward-looking statements. The Company assumes no obligation to update any forward-looking statements, except as required by applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

XPhyto Therapeutics $XPHY.ca $XPHYF Signs German Distribution, Storage and Logistics Agreement for 25-Minute COVID-19 PCR Test $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 8:21 AM on Wednesday, April 21st, 2021
http://blog.agoracom.com/wp-content/uploads/2021/01/XPHYTO-70-x-70.jpg

XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that it has entered into an agreement (the “Agreement”) with an established German pharmaceutical wholesaler and service provider (the “Distributor”) for the distribution, storage and logistics of XPhyto’s diagnostic products in Germany. The Agreement secures XPhyto a full-service distribution partner for its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”). Covid-ID Lab is registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.

Pursuant to the Agreement, the Distributor will distribute, store and deliver Covid-ID Lab test kits according to the product specifications and all applicable regulations to XPhyto’s customers. In addition, the Distributor will provide the documentation and fulfillment of storage obligations, the fulfillment of reporting and notification obligations, and the processing of any returned products. The obligations and services to be rendered under the Agreement satisfy all of the logistical and regulatory requirements for the commercial sale of COVID-ID Lab in Germany.

“With this agreement, we have secured a strong partner with an established medical distribution network throughout Germany. This is an exciting and critical step towards commercial sales of COVID-ID Lab,” said Hugh Rogers, CEO and Director of XPhyto. “The Company’s commercialization strategy is focused on the German market for initial product launch and the creation of robust and sustainable sales.”

Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. Covid-ID Lab requires only a single 20-minute PCR thermal cycle for assay performance without prior RNA extraction as part of the sample preparation. Many widely available standard PCR instruments are suitable to run the test. Results are collected after the PCR cycle via easy-to-read optical indicator strips on a simple fluidics platform. The elimination of RNA extraction for sample preparation reduces cross-contamination risk and minimizes the need for lab materials and trained personnel. The rapid results, minimal laboratory equipment, and ease of use are expected to translate into reduced operating costs, greater convenience and portability.

XPhyto is currently in discussions with various potential customers, distribution and wholesale partners as well as potential licensees. The sales launch in Europe is targeted for April 2021. The Company will provide further information and updates in due course.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

Read More:https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/759431-xphyto-signs-german-distribution-storage-and-logistics-agreement-for-25-minute-covid-19-pcr-test/messages/2312832#message

XPhyto Therapeutics $XPHY.ca $XPHYF Adds Top-Level Executive Talent to its Global Operations $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 8:12 AM on Tuesday, April 20th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/01/XPHYTO-70-x-70.jpg
  • Mr. Wolfgang Probst appointed as the Chief Operations Officer (COO) of XPhyto
  • Addition of Mr. Manfred Buchberger as the Head of Corporate Development

XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce the appointment of Mr. Wolfgang Probst as the Chief Operations Officer (COO) of XPhyto and the addition of Mr. Manfred Buchberger as the Head of Corporate Development at XP Diagnostics GmbH (“XP Diagnostics”), a wholly owned German subsidiary of the Company. With European CE-IVD approval announced March 18, 2021, for the Company’s lead diagnostic product, Covid-ID Lab, XPhyto continues to enhance its commercial team as it anticipates near-term distribution and sales.

Mr. Probst is an experienced management and finance consultant with expertise in mergers and acquisitions, corporate re-organizations, and divestitures. He has a proven track record of leadership, strategic planning, and organizational restructuring having guided multiple startups from inception to financial success. Mr. Probst was responsible for successfully structuring XPhyto’s European operations and establishing associated partnerships and collaborations, both commercial and academic. As the newly appointed COO of XPhyto, Mr. Probst will be responsible for managing the Company’s global operations. Mr. Probst will remain a director of XPhyto and the managing director of XP Diagnostics.

Mr. Buchberger is a global leader in the medical diagnostics industry. For almost a decade, he was the CEO and a member of the Global Management Board of a major European medical diagnostics and analytics company with annual revenues of over 600 million Euro. His addition to the Company brings decades of diagnostics industry experience focused on international business development, sales, marketing, and product management. Mr. Buchberger has successfully created, implemented, and managed business growth strategies across Europe, North and South America, Middle East and Asia, including the successful launch of new medical diagnostic products.

On March 18, 2021, XPhyto announced European commercial approval of Covid-ID Lab, a rapid 25-minute point-of-care PCR test for COVID-19. Mr. Probst and Mr. Buchberger will be responsible for executing the global product launch and businesses development of Covid-ID Lab.

Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. Covid-ID Lab requires only a single 20-minute PCR thermal cycle for assay performance without prior RNA extraction as part of the sample preparation. Many widely available standard PCR instruments are suitable to run the test. Results are collected after the PCR cycle via easy-to-read optical indicator strips on a simple fluidics platform. The elimination of RNA extraction for sample preparation reduces cross-contamination risk and minimizes the need for lab materials and trained personnel. The rapid results, minimal laboratory equipment, and ease of use are expected to translate into reduced operating costs, greater convenience and portability.

Read More: https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/759347-xphyto-adds-top-level-executive-talent-to-its-global-operations/messages/2312660#message

Predictiv AI $PAI.ca $INOTF Signs F2 Factor to Provide Strategic Support Services, Bolster Sales, and Increase Distribution $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 9:51 AM on Tuesday, April 13th, 2021
Predictiv AI

TORONTO , April 13, 2021 /CNW/ – Predictiv AI Inc. TSXV: PAI) (OTC: INOTF) (FSE: 71TA ) (” Predictiv AI ” or the ” Company “), a software and solutions provider in the artificial intelligence markets, is pleased to announce that it has entered into a consultancy agreement, effective immediately, with F2 Factor (“F2”) to provide strategic support services to the Predictiv AI leadership team, and to increase sales and distribution across brands and products.

As a leader in multichannel marketing, sales, and distribution, F2 Factor is a firm which works in tandem with leading businesses to build and execute their sales strategy. The firm is led by Mark Collins who will be working directly with the leadership team at Predictiv AI. 

As a seasoned executive, Mark has built a track record of success, winning numerous awards throughout his career with GE and Cisco. Mark has played a leadership role in building multiple $100m franchises within global companies and worked with many start-up and scale-up companies over the years.

“Predictiv AI has already demonstrated an ability to bring cutting-edge technology to market at the right time to set the foundation for enabling intelligent infrastructure and controls for shared spaces that are game changing”, said Mark Collins, President of F2 Factor.

Read More: https://agoracom.com/ir/PredictivAI/forums/discussion/topics/758954-predictiv-ai-signs-f2-factor-to-provide-strategic-support-services-bolster-sales-and-increase-distribution/messages/2311736#message

VIDEO – Predictiv AI’s $PAI.ca $INOTF Landmark South Florida Hospital Deal for ThermalPass Scanning Devices puts AI Firm in Driving Seat $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 6:25 PM on Monday, April 12th, 2021
Predictiv AI

Predictiv AI’s proprietary artificial intelligence and machine learning platform provides predictive and prescriptive solutions in the public safety sector.

Its flagship product is its ThermalPass temperature scanning devices, which use cutting edge tech to mitigate the spread of contagions in public places, such as factories, supermarkets, schools, office buildings, mass-transit stations, hospitals and long-term care facilities.

  • 24 medical grade sensors
  • 1,200 readings per second
  • 1 person / second
  • Received orders for 90+ units of ThermalPass following commercial launch in October 2020

The company this month secured backing from one of the largest and most respected hospitals in the U.S., with a game-changing deal to install multiple ThermalPass temperature scanning devices in Memorial Healthcare System’s flagship South Florida hospital and its six-hospital network.

$PAI has also been making strides with its subsidy Weather Telematics, which:

  • Launched its Alert Fleet product, a road weather hazard alert system for commercial fleets.
  • Alert Fleet advises drivers of dangerous conditions, such as black ice or hydroplaning, 200 metres ahead, thus providing time to mitigate risk and avoid accidents
  • Recent partnership with Propel IT to accelerate commercialization of IT SAAS Fleet Safety Platform

The latter partnership will significantly enhance available real-time data access for drivers and dispatchers.   

Michael Lende, Predictiv AI’s CEO and President, breaks down the news: